휴온스글로벌 로고

Huonslab Confirms Recombinant Human Hyaluronidase Effectiveness

- Equivalent to the original... Improved reliability - 

On the 24th day, Huonslab, a subsidiary of Huons Group announced that it conducted additional comparative tests on the HLB3-002(Recombinant human hyaluronidase) with the original drug (Halozyme’s Hyaluronidase) and confirmed reliable equivalent efficacy results.

The official said that although this result had already been confirmed to be equivalent to the original in an efficacy test conducted earlier this year, more accurate and reliable data were secured through this test.

This test was conducted through domestic CRO, the pharmacokinetics and diffusion effect of the drug were analyzed for 28 days after subcutaneous administration to the Mabthera I.V+HLB3-002 group and the Mabthera S.C group, respectively. As a result, it was confirmed that the pharmacokinetics and efficacy of the two groups were equivalent.

Lim, Research Director of Huonslab announced that Non-clinical toxicity testing for HLB3-002 is going smoothly, clinical applications (IND) will be available early next year, and further accelerate clinical trials with the goal of obtaining HLB3-002 approval at the end of 2025.

For successful development of HLB3-002, Huonslab is making companywide efforts, such as establishing a new development department, integrating related departments, and expanding cooperation partners.

About Hyaluronidase, Hyaluronidase is an enzyme that decomposes Hyaluronic acid existing under human skin. It increases the permeability of the subcutaneous tissue, increases the diffusion rate of the drug, and promotes it to be absorbed into the capillary vessels inside the skin, so it is used as a drug diffusion agent.